Ocugen (OCGN) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Mobile

donwloadimg

moomoo Desktop

The next-gen workspace

Click to view more download content

Sign up/Log in

English
中文繁體
中文简体

Dark
Light

Open Account

US Stock MarketDetailed Quotes

OCGN Ocugen

Watchlist

0.7179
+0.0152+2.16%

Close Feb 14 16:00 ET

0.7198
+0.0019+0.26%

Post 20:01 ET

208.87MMarket Cap-3.78P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Maxim Group Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $4
Moomoo NewsFeb 14 15:31 ET · Ratings
Buy Rating for Ocugen Based on Promising OCU410 Study Progress and Geographic Atrophy Treatment Potential
TipRanksFeb 14 15:05 ET · Ratings
Why Ocugen (OCGN) Is Advancing Today
Yahoo FinanceFeb 13 17:41 ET
Ocugen Inc. Stock Advances 6.5%, Outperforms Market
Dow JonesFeb 13 16:39 ET
Analysts Offer Insights on Healthcare Companies: Ocugen (OCGN) and Xilio Therapeutics (XLO)
TipRanksFeb 13 10:50 ET · Ratings
HC Wainwright & Co. Maintains Buy on Ocugen, Raises Price Target to $8
BenzingaFeb 13 06:49 ET · Ratings

Comments

$Ocugen (OCGN.US)$ i am not going to sell this

1

Always Diamond Hand

hi

$Ocugen (OCGN.US)$ 0.6 and I am in

$Ocugen (OCGN.US)$ the most useless stock l ever bought

2

$Ocugen (OCGN.US)$ the more good news we get the more drops

2

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related M

$Ocugen (OCGN.US)$
Stock Market News Live Feed

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related M

1

Read more